Hypoglycemic agents and potential anti-inflammatory activity

References

• Centers for Disease Control and PreventionDiabetes Report Card 2014Atlanta, GACenters for Disease Control and Prevention, US Dept of Health and Human Services2015
   Google Scholar
• D’AdamoECaprioSType 2 diabetes in youth: epidemiology and pathophysiologyDiabetes Care201134S161S16521525449
   PubMed Web of Science ®Google Scholar
• GillespieKMType 1 diabetes: pathogenesis and preventionCMAJ200617516517016847277
   PubMed Web of Science ®Google Scholar
• GarberAJAbrahamsonMJBarzilayJIAACE/ACE comprehensive diabetes management algorithm 2015Endocr Pract20152143844725877012
   PubMed Web of Science ®Google Scholar
• Standards of medical care in diabetes–2015: summary of revisionsDiabetes Care201538SupplS4
   Google Scholar
• LuftVCSchmidtMIPankowJSChronic inflammation role in the obesity-diabetes association: a case-cohort studyDiabetol Metab Syndr201353123806173
   PubMed Web of Science ®Google Scholar
• EsserNLegrand-PoelsSPietteJInflammation as a link between obesity, metabolic syndrome and type 2 diabetesDiabetes Res Clin Pract201410514115024798950
   PubMed Web of Science ®Google Scholar
• WellenKEHotamisligilGSInflammation, stress, and diabetesJ Clin Invest20051151111111915864338
   PubMed Web of Science ®Google Scholar
• NavarroJFMoraCRole of inflammation in diabetic complicationsNephrol Dial Transplant2005202601260416188894
   PubMed Web of Science ®Google Scholar
• DeFronzoRAFrom the triumvirate to the ominous Octet: a new paradigm for the treatment of type 2 diabetes mellitusDiabetes20095877379519336687
   PubMed Web of Science ®Google Scholar
• FonsecaVADefining and characterizing the progression of type 2 diabetesDiabetes Care200932S151S15619875543
   PubMed Web of Science ®Google Scholar
• BloomgardenZTHandelsmanYApproaches to treatment 2: comparison of AACE and ADA type 2 diabetes treatment guidelinesJ Diabetes2015814626431291
   PubMed Web of Science ®Google Scholar
• ShoelsonSELeeJGoldfineABInflammation and insulin resistanceJ Clin Invest20061161793180116823477
   PubMed Web of Science ®Google Scholar
• HotamisligilGSShargillNSSpiegelmanBMAdipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistanceScience199325987917678183
   PubMed Web of Science ®Google Scholar
• PickupJCCrookMAIs type II diabetes mellitus a disease of the innate immune system?Diabetologia199841124112489794114
   PubMed Web of Science ®Google Scholar
• SprangerJKrokeAMöhligMInflammatory cytokines and the risk to develop type 2 diabetes: results of the prospective population-based European Prospective Investigation into Cancer and Nutrition (EPIC)-Potsdam StudyDiabetes20035281281712606524
   PubMed Web of Science ®Google Scholar
• KingGLThe role of inflammatory cytokines in diabetes and its complicationsJ Periodontol2008791527153418673007
   PubMed Web of Science ®Google Scholar
• SurmiBKHastyAHMacrophage infiltration into adipose tissue: initiation, propagation and remodelingFuture Lipidol2008354555618978945
   PubMed Web of Science ®Google Scholar
• LumengCNBodzinJLSaltielARObesity induces a phenotypic switch in adipose tissue macrophage polarizationJ Clin Invest200711717518417200717
   PubMed Web of Science ®Google Scholar
• CerneaSDobreanuMDiabetes and beta cell function: from mechanisms to evaluation and clinical implicationsBiochem Med (Zagreb)20132326628024266296
   PubMed Web of Science ®Google Scholar
• SellHHabichCEckelJAdaptive immunity in obesity and insulin resistanceNat Rev Endocrinol2012870971622847239
   PubMed Web of Science ®Google Scholar
• DandonaPChaudhuriAGhanimHInsulin as an anti-inflammatory and antiatherogenic modulatorJ Am Coll Cardiol200953S14S2019179212
   PubMed Web of Science ®Google Scholar
• DandonaPChaudhuriAAnti-inflammatory and antiatherogenic effects of insulinInsulin20061Suppl 1S11S17
   Google Scholar
• NgKWAllenMLDesaiACardioprotective effects of insulin: how intensive insulin therapy may benefit cardiac surgery patientsCirculation201212572172822311884
   PubMed Web of Science ®Google Scholar
• MaoXMLiuHTaoXJIndependent anti-inflammatory effect of insulin in newly diagnosed type 2 diabetesDiabetes Metab Res Rev20092543544119405039
   PubMed Web of Science ®Google Scholar
• GhanimHMohantyPDeopurkarRAcute modulation of toll-like receptors by insulinDiabetes Care2008311827183118556339
   PubMed Web of Science ®Google Scholar
• NiswenderKEarly and aggressive initiation of insulin therapy for type 2 diabetes: what is the evidence?Clin Diabetes2009276068
   Google Scholar
• MeneghiniLFEarly insulin treatment in type 2 diabetesDiabetes Care200932S266S26919875562
   PubMed Web of Science ®Google Scholar
• The Action to Control Cardiovascular Risk in Diabetes Study GroupEffects of intensive glucose lowering in type 2 diabetesN Engl J Med20083582545255918539917
   PubMed Web of Science ®Google Scholar
• TakebayashiKAsoYInukaiTInitiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetesMetab Clin Exp20045369369915164314
   PubMed Web of Science ®Google Scholar
• Da SilvaAMVde Moraes PennoLBertoluciMCInsulin therapy does not interfere with venous endothelial function evaluation in patients with type 2 diabetes mellitusClinics (Sao Paulo)2010651139114221243287
   PubMed Web of Science ®Google Scholar
• PfütznerASchöndorfTHanefeldMHigh-sensitivity C-reactive protein predicts cardiovascular risk in diabetic and nondiabetic patients: effects of insulin-sensitizing treatment with pioglitazoneJ Diabetes Sci Technol2010470671620513338
   PubMedGoogle Scholar
• PradhanADEverettBMCookNREffects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trialJAMA20093021186119419755697
   PubMed Web of Science ®Google Scholar
• JansenHJStienstraRvan DiepenJAStart of insulin therapy in patients with type 2 diabetes mellitus promotes the influx of macrophages into subcutaneous adipose tissueDiabetologia2013562573258124065152
   PubMed Web of Science ®Google Scholar
• GaldoJAThurstonMMBourgCAClinical considerations for insulin pharmacotherapy in ambulatory care, part one: introduction and review of current products and guidelinesClin Diabetes201432667526130864
   PubMedGoogle Scholar
• WangXCGusdonAMLiuHEffects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammationWorld J Gastroenterol201420148211483025356042
   PubMed Web of Science ®Google Scholar
• AvogaroAVigili de KreutzenbergSFadiniGPCardiovascular actions of GLP-1 and incretin-based pharmacotherapyCurr Diab Rep20141448324676508
   PubMed Web of Science ®Google Scholar
• Pi-SunyerXAstrupAFujiokaKA randomized, controlled trial of 3.0 mg of liraglutide in weight managementN Engl J Med2015373112226132939
   PubMed Web of Science ®Google Scholar
• LiuJWangGJiaYGLP-1 receptor agonists: effects on the progression of non-alcoholic fatty liver diseaseDiabetes Metab Res Rev20153132933525066109
   PubMed Web of Science ®Google Scholar
• LeeYSParkMSChoungJSGlucagon-like peptide-1 inhibits adipose tissue macrophage infiltration and inflammation in an obese mouse model of diabetesDiabetologia2012552456246822722451
   PubMed Web of Science ®Google Scholar
• SaishoYMetformin and inflammation: its potential beyond glucoselowering effectEndocr Metab Immune Disord Drug Targets20151519620525772174
   PubMed Web of Science ®Google Scholar
• IsodaKYoungJLZirlikAMetformin inhibits proinflammatory responses and nuclear factor-kappaB in human vascular wall cellsArterioscler Thromb Vasc Biol20062661161716385087
   PubMed Web of Science ®Google Scholar
• KimSAChoiHCMetformin inhibits inflammatory response via AMPK-PTEN pathway in vascular smooth muscle cellsBiochem Biophys Res Commun201242586687222898050
   PubMed Web of Science ®Google Scholar
• ZhengZChenHLiJSirtuin 1-mediated cellular metabolic memory of high glucose via the LKB1/AMPK/ROS pathway and therapeutic effects of metforminDiabetes20126121722822124463
   PubMed Web of Science ®Google Scholar
• Ruggiero-LopezDLecomteMMoinetGReaction of metformin with dicarbonyl compounds. Possible implication in the inhibition of advanced glycation end product formationBiochem Pharmacol1999581765177310571251
   PubMed Web of Science ®Google Scholar
• HaffnerSTemprosaMCrandallJIntensive lifestyle intervention or metformin on inflammation and coagulation in participants with impaired glucose toleranceDiabetes2005541566157215855347
   PubMed Web of Science ®Google Scholar
• KrysiakROkopienBThe effect of metformin on monocyte secretory function in simvastatin-treated patients with impaired fasting glucoseMetab Clin Exp201362394322841520
   PubMed Web of Science ®Google Scholar
• KrysiakROkopienBLymphocyte-suppressing and systemic anti-inflammatory effects of high-dose metformin in simvastatin-treated patients with impaired fasting glucoseAtherosclerosis201222540340723107042
   PubMed Web of Science ®Google Scholar
• SobelBEHardisonRMGenuthSProfibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trialCirculation201112469570321768545
   PubMed Web of Science ®Google Scholar
• DerosaGCarboneAD’AngeloAVariations in inflammatory biomarkers following the addition of sitagliptin in patients with type 2 diabetes not controlled with metforminIntern Med2013522179218724088749
   PubMed Web of Science ®Google Scholar
• ProksPReimannFGreenNSulfonylurea stimulation of insulin secretionDiabetes200251Suppl 3S368S37612475777
   PubMed Web of Science ®Google Scholar
• LingMYMaZYWangYYUp-regulated ATP-sensitive potassium channels play a role in increased inflammation and plaque vulnerability in macrophagesAtherosclerosis201322634835523218803
   PubMed Web of Science ®Google Scholar
• CaiJLuSYaoZDengYPGlibenclamide attenuates myocardial injury by lipopolysaccharides in streptozotocin-induced diabetic miceCardiovasc Diabetol20141310625077824
   PubMed Web of Science ®Google Scholar
• Mu-HuoJJiao-JiaoYLin-ShaJGlibenclamide pretreatment attenuates acute lung injury by inhibiting the inflammatory responses and oxidative stress in a polymicrobial sepsis animal modelJAPM201413643
   Google Scholar
• SimardJMGengZWooSKGlibenclamide reduces inflammation, vasogenic edema, and caspase-3 activation after subarachnoid hemorrhageJ Cereb Blood Flow Metab20092931733018854840
   PubMed Web of Science ®Google Scholar
• KewcharoenwongCRinchaiDUtispanKGlibenclamide reduces pro-inflammatory cytokine production by neutrophils of diabetes patients in response to bacterial infectionSci Rep20133336324285369
   PubMed Web of Science ®Google Scholar
• MavridisGSouliouEDizaEInflammatory cytokines in insulin-treated patients with type 2 diabetesNutr Metab Cardiovasc Dis20081847147617976964
   PubMed Web of Science ®Google Scholar
• CuiWZhangSCaiZThe antidiabetic agent glibenclamide protects airway hyperresponsiveness and inflammation in miceInflammation20153883584525113133
   PubMed Web of Science ®Google Scholar
• DerosaGD’AngeloASalvadeoSATModification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjectsMicrovasc Res20107914414920079360
   PubMed Web of Science ®Google Scholar
• DerosaGD’AngeloASalvadeoSATOral glucose tolerance test effects on endothelial inflammation markers in healthy subjects and diabetic patientsHorm Metab Res20104281319735057
   PubMed Web of Science ®Google Scholar
• FukayaNMochizukiKShimadaMThe alpha-glucosidase inhibitor miglitol decreases glucose fluctuations and gene expression of inflammatory cytokines induced by hyperglycemia in peripheral leukocytesNutrition20092565766719216056
   PubMed Web of Science ®Google Scholar
• DerosaGMaffioliPD’AngeloAAcarbose on insulin resistance after an oral fat load: a double-blind, placebo controlled studyJ Diabetes Complications20112525826621367625
   PubMed Web of Science ®Google Scholar
• DerosaGMaffioliPFerrariIAcarbose actions on insulin resistance and inflammatory parameters during an oral fat loadEur J Pharmacol201165124025021118681
   PubMed Web of Science ®Google Scholar
• EmotoTSawadaTHashimotoMEffect of 3-month repeated administration of miglitol on vascular endothelial function in patients with diabetes mellitus and coronary artery diseaseAm J Cardiol2012109424621944671
   PubMed Web of Science ®Google Scholar
• ShimazuTInamiNSatohDEffect of acarbose on platelet-derived microparticles, soluble selectins, and adiponectin in diabetic patientsJ Thromb Thrombolysis20092842943519137265
   PubMed Web of Science ®Google Scholar
• FujitakaKOtaniHJoFComparison of metabolic profile and adiponectin level with pioglitazone versus voglibose in patients with type-2 diabetes mellitus associated with metabolic syndromeEndocr J20115842543221498915
   PubMed Web of Science ®Google Scholar
• TungDCheungPHCiallellaJNovel anti-inflammatory effects of repaglinide in rodent models of inflammationPharmacology20118829530122086064
   PubMed Web of Science ®Google Scholar
• YamazakiMHasegawaGMajimaSEffect of repaglinide versus glimepiride on daily blood glucose variability and changes in blood inflammatory and oxidative stress markersDiabetol Metab Syndr201465424843385
   PubMed Web of Science ®Google Scholar
• AssaloniRDa RosRQuagliaroLEffects of S21403 (mitiglinide) on postprandial generation of oxidative stress and inflammation in type 2 diabetic patientsDiabetologia2005481919192416007412
   PubMed Web of Science ®Google Scholar
• GumieniczekAHopkałaHRoli skiJAntioxidative and anti-inflammatory effects of repaglinide in plasma of diabetic animalsPharmacol Res20055216216615967382
   PubMed Web of Science ®Google Scholar
• LundSSTarnowLStehouwerCDAImpact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetesEur J Endocrinol200815863164118426821
   PubMed Web of Science ®Google Scholar
• HolmanRRHaffnerSMMcMurrayJJEffect of nateglinide on the incidence of diabetes and cardiovascular eventsN Engl J Med20103621463147620228402
   PubMed Web of Science ®Google Scholar
• Ju-MingLXiao-HuiGXiao-FengLEffects of nateglinide on postprandial plasma glucose excursion and metabolism of lipids in Chinese patients with type 2 diabetes: a 4-week, randomized, active-control, open-label, parallel-group, multicenter trialCurr Med Res Opin Epub2012719
   Google Scholar
• CorzoCGriffinPRTargeting the peroxisome proliferator-activated receptor-γ to counter the inflammatory milieu in obesityDiabetes Metab J20133739540324404510
   PubMedGoogle Scholar
• IalentiAGrassiaGDi MeglioPMechanism of the anti-inflammatory effect of thiazolidinediones: relationship with the glucocorticoid pathwayMol Pharmacol2005671620162815684043
   PubMed Web of Science ®Google Scholar
• KoppakaSKehlenbrinkSCareyMReduced adipose tissue macrophage content is associated with improved insulin sensitivity in thiazolidinedione-treated diabetic humansDiabetes2013621843185423349486
   PubMed Web of Science ®Google Scholar
• SzantoANagyLThe many faces of PPARgamma: anti-inflammatory by any means?Immunobiology200821378980318926294
   PubMed Web of Science ®Google Scholar
• PowellLACrowePKankaraCRestoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulationClin Sci201212313514622309242
   PubMed Web of Science ®Google Scholar
• EstersonYBZhangKKoppakaSInsulin sensitizing and anti-inflammatory effects of thiazolidinediones are heightened in obese patientsJ Investig Med20136111521160
   Web of Science ®Google Scholar
• KodamaNTaharaNTaharaAEffects of pioglitazone on visceral fat metabolic activity in impaired glucose tolerance or type 2 diabetes mellitusJ Clin Endocrinol Metab2013984438444524030946
   PubMed Web of Science ®Google Scholar
• CipollettaDFeuererMLiAPPAR-γ is a major driver of the accumulation and phenotype of adipose tissue Treg cellsNature201248654955322722857
   PubMed Web of Science ®Google Scholar
• ShyangdanDClarCGhouriNInsulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic reviewHealth Technol Assess201115111022059955
   PubMed Web of Science ®Google Scholar
• BoettcherECsakoGPucinoFMeta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitisAliment Pharmacol Ther201235667522050199
   PubMed Web of Science ®Google Scholar
• PlutzkyJThe potential role of peroxisome proliferator-activated receptors on inflammation in type 2 diabetes mellitus and atherosclerosisAm J Cardiol20039234J41J
   Web of Science ®Google Scholar
• NittaYTaharaNTaharaAPioglitazone decreases coronary artery inflammation in impaired glucose tolerance and diabetes mellitus: evaluation by FDG-PET/CT imagingJACC Cardiovasc Imaging201361172118224229770
   PubMed Web of Science ®Google Scholar
• MizoguchiMTaharaNTaharaAPioglitazone attenuates atherosclerotic plaque inflammation in patients with impaired glucose tolerance or diabetes a prospective, randomized, comparator-controlled study using serial FDG PET/CT imaging study of carotid artery and ascending aortaJACC Cardiovasc Imaging201141110111821999871
   PubMed Web of Science ®Google Scholar
• MarfellaRD’AmicoMEspositoKThe ubiquitin-proteasome system and inflammatory activity in diabetic atherosclerotic plaques: effects of rosiglitazone treatmentDiabetes20065562263216505224
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJWolskiKComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialJAMA20082991561157318378631
   PubMed Web of Science ®Google Scholar
• ChenRYanJLiuPWangZEffects of thiazolidinedione therapy on inflammatory markers of type 2 diabetes: a meta-analysis of randomized controlled trialsPLoS ONE201510e012370325897968
   PubMed Web of Science ®Google Scholar
• ZhaoYHeXHuangCThe impacts of thiazolidinediones on circulating C-reactive protein levels in different diseases: a meta-analysisDiabetes Res Clin Pract20109027928720926154
   PubMed Web of Science ®Google Scholar
• KaragiannisEPfütznerAForstTThe IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditionsDiabetes Technol Ther20081020621218473695
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJASecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet20053661279128916214598
   PubMed Web of Science ®Google Scholar
• UssherJRDruckerDJCardiovascular biology of the incretin systemEndocr Rev20123318721522323472
   PubMed Web of Science ®Google Scholar
• ScheenAJCardiovascular effects of gliptinsNat Rev Cardiol201310738423296071
   PubMed Web of Science ®Google Scholar
• ZhaoYYangLZhouZDipeptidyl peptidase-4 inhibitors: multi-target drugs, not only antidiabetes drugsJ Diabetes20146212923683065
   PubMed Web of Science ®Google Scholar
• AvogaroAFadiniGPThe effects of dipeptidyl peptidase-4 inhibition on microvascular diabetes complicationsDiabetes Care2014372884289425249673
   PubMed Web of Science ®Google Scholar
• HirakawaHZempoHOgawaMA DPP-4 inhibitor suppresses fibrosis and inflammation on experimental autoimmune myocarditis in micePLoS ONE201510e011936025768281
   PubMed Web of Science ®Google Scholar
• SchürmannCLinkeAEngelmann-PilgerKThe dipeptidyl peptidase-4 inhibitor linagliptin attenuates inflammation and accelerates epithelialization in wounds of diabetic ob/ob miceJ Pharmacol Exp Ther2012342718022493041
   PubMed Web of Science ®Google Scholar
• TaNNSchuylerCALiYDPP-4 (CD26) inhibitor alogliptin inhibits atherosclerosis in diabetic apolipoprotein E-deficient miceJ Cardiovasc Pharmacol20115815716621558879
   PubMed Web of Science ®Google Scholar
• DaiYDaiDWangXDPP-4 inhibitors repress NLRP3 inflammasome and interleukin-1beta via GLP-1 receptor in macrophages through protein kinase C pathwayCardiovasc Drugs Ther20142842543225022544
   PubMed Web of Science ®Google Scholar
• ShinjoTNakatsuYIwashitaMDPP-IV inhibitor anagliptin exerts anti-inflammatory effects on macrophages, adipocytes, and mouse livers by suppressing NF-κB activationAm J Physiol Endocrinol Metab2015309E214E22326015438
   PubMed Web of Science ®Google Scholar
• MakdissiAGhanimHVoraMSitagliptin exerts an antiinflammatory actionJ Clin Endocrinol Metab2012973333334122745245
   PubMed Web of Science ®Google Scholar
• TremblayAJLamarcheBDeaconCFEffects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetesMetab Clin Exp2014631141114825034387
   PubMed Web of Science ®Google Scholar
• KlempfnerRLeorJTenenbaumAEffects of a vildagliptin/metformin combination on markers of atherosclerosis, thrombosis, and inflammation in diabetic patients with coronary artery diseaseCardiovasc Diabetol2012116022672501
   PubMed Web of Science ®Google Scholar
• Satoh-AsaharaNSasakiYWadaHA dipeptidyl peptidase-4 inhibitor, sitagliptin, exerts anti-inflammatory effects in type 2 diabetic patientsMetab Clin Exp20136234735123062489
   PubMed Web of Science ®Google Scholar
• MatsubaraJSugiyamaSAkiyamaEDipeptidyl peptidase-4 inhibitor, sitagliptin, improves endothelial dysfunction in association with its anti-inflammatory effects in patients with coronary artery disease and uncontrolled diabetesCirc J2013771337134423386232
   PubMed Web of Science ®Google Scholar
• DerosaGMaffioliPSalvadeoSATEffects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patientsMetab Clin Exp20105988789520015525
   PubMed Web of Science ®Google Scholar
• NakamuraYTsujiMHasegawaHAnti-inflammatory effects of linagliptin in hemodialysis patients with diabetesHemodial Int20141843344224405885
   PubMed Web of Science ®Google Scholar
• ScheenAJPharmacodynamics, efficacy and safety of sodium-glucose co-transporter type 2 (SGLT2) inhibitors for the treatment of type 2 diabetes mellitusDrugs201575335925488697
   PubMed Web of Science ®Google Scholar
• TaharaAKurosakiEYokonoMEffects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic ratsJ Pharm Pharmacol20146697598724533859
   PubMed Web of Science ®Google Scholar
• TaharaAKurosakiEYokonoMEffects of SGLT2 selective inhibitor ipragliflozin on hyperglycemia, hyperlipidemia, hepatic steatosis, oxidative stress, inflammation, and obesity in type 2 diabetic miceEur J Pharmacol201371524625523707905
   PubMed Web of Science ®Google Scholar
• HermansenKMortensenLSHermansenM-LCombining insulins with oral antidiabetic agents: effect on hyperglycemic control, markers of cardiovascular risk and diseaseVasc Health Risk Manag2008456157418827907
   PubMedGoogle Scholar
• SchöndorfTMusholtPBHohbergCThe fixed combination of pioglitazone and metformin improves biomarkers of platelet function and chronic inflammation in type 2 diabetes patients: results from the PIOfix studyJ Diabetes Sci Technol2011542643221527115
   PubMedGoogle Scholar
• HanefeldMPioglitazone and sulfonylureas: effectively treating type 2 diabetesInt J Clin Pract Suppl200761Suppl 153202717594390
   PubMedGoogle Scholar
• DerosaGFranzettiIGQuerciFVariation in inflammatory markers and glycemic parameters after 12 months of exenatide plus metformin treatment compared with metformin alone: a randomized placebo-controlled trialPharmacotherapy20133381782623744726
   PubMed Web of Science ®Google Scholar
• ChenLKleinTLeungPSEffects of combining linagliptin treatment with BI-38335, a novel SGLT2 inhibitor, on pancreatic islet function and inflammation in db/db miceCurr Mol Med201212995100422804249
   PubMed Web of Science ®Google Scholar
• NauckMAUpdate on developments with SGLT2 inhibitors in the management of type 2 diabetesDrug Des Dev Ther2014813351380
   PubMed Web of Science ®Google Scholar
• GroverJKYadavSVats V. Medicinal plants of India with anti-diabetic potentialJ Ethnopharmacol2002818110012020931
   PubMed Web of Science ®Google Scholar
• GroverJKVatsVYadavSEffect of feeding aqueous extract of Petro-carpus marsupium on glycogen content of tissues and the key enzymes of carbohydrate metabolismMolecular and Cellular Biochemistry2002241535912482025
   PubMed Web of Science ®Google Scholar
• BabuPVALiuDGreen tea catechins and cardiovascular health: an updateCurr Med Chem2008151840185018691042
   PubMed Web of Science ®Google Scholar
• FarrarMDNicolaouAClarkeKAA randomized controlled trial of green tea catechins in protection against ultraviolet radiation- induced cutaneous inflammationAm J Clin Nutr201510260861526178731
   PubMed Web of Science ®Google Scholar
• SattiNKChauhanPSDuttPAmelioration of inflammatory responses by chlorogenic acid via suppression of pro-inflammatory mediatorsJ Appl Pharm Sci201116775
   Google Scholar
• ShinHSSatsuHBaeMJAnti-inflammatory effect of chlorogenic acid on the IL-8 production in Caco-2 cells and the dextran sulphate sodium-induced colitis symptoms in C57BL/6 miceFood Chem201516816717525172696
   PubMed Web of Science ®Google Scholar
• GonzálezRBallesterILópez-PosadasREffects of flavonoids and other polyphenols on inflammationCrit Rev Food Sci Nutr20115133136221432698
   PubMed Web of Science ®Google Scholar
• LeeYJungJCAliZKhanIAOhSAnti-inflammatory effect of triterpene saponins isolated from blue cohosh (caulophyllum thalictroides)Evid Based Complement Alternat Med2012201279819222988475
   PubMed Web of Science ®Google Scholar